Abivax Spots an Extra Benefit of its Potential HIV Cure

Phase IIa data confirms that Abivax’s potential HIV cure not only reduces viral reservoir but it also has anti-inflammatory effects.

Abivax targets the immune system to fight viral infections, including human immunodeficiency virus (HIV), as well as autoimmune diseases. The company has now confirmed the preliminary results from its first cohort of patients in a recent Phase IIa trial. Abivax’s HIV drug, ABX464, significantly reduced patients’ HIV reservoirs over a 28-day period. In addition, the drug had anti-inflammatory effects on rectal tissue, which supports its use for the treatment of inflammatory diseases like ulcerative colitis. This news has caused Abivax’s stock price to rocket by more than 30% this morning as confidence grows in the company’s technology.

A limitation of this first cohort of patients has been a lack of data due to “rectal biopsies did not yield enough HIV DNA to make an assessment of the viral reservoir,” as CMO Jean-Marc Steens explained. The company has made changes to make sure that enough high-quality viral DNA is available” in the second cohort of 12 patients. Over 3 months, Abivax will investigate a 50mg daily dose of ABX464, as opposed to the 150mg dose used in the first cohort. Any changes in HIV reservoir and inflammation levels during the study will be followed by the regular and pre-specified sampling of blood and rectal tissue.


Image – Maksim Kryuchkov / shutterstock.com

Support good journalism, subscribe to Labiotech Insider

Labiotech Insider

If you liked this post and want to read more good journalism, support us by joining Labiotech Insider. Our Insider membership gives you access to exclusive content and other advantages.

We use cookies to give you the best experience. If you click on accept, we also use tracking cookies for analytics and advertising purposes. Check our privacy policy for more details. By accepting, you support our independent media and its’ freely accessible content. You may withdraw your consent at any time.